<DOC>
	<DOCNO>NCT01052389</DOCNO>
	<brief_summary>The GiSAS study multi-centre randomized clinical trial involve 80 italian community psychiatric service Italy recruit 800 patient affected schizophrenia . In sample schizophrenic outpatient , hypothesize significant difference overall tolerability effectiveness aripiprazole , olanzapine haloperidol 12 month . It pragmatic trial . Thus , participant select represent broad range `` real-world '' patient , treatment medication non-blinded randomization , assign drug prescribe accord usual care practice . The measure effectiveness retention patient assign treatment . The measure tolerability onset metabolic syndrome .</brief_summary>
	<brief_title>Pragmatic RCT Comparing Aripiprazole , Olanzapine Haloperidol Treatment Schizophrenia</brief_title>
	<detailed_description>Specific aim . The GiSAS study randomize control superiority trial aim evaluate tolerability effectiveness aripiprazole , olanzapine haloperidol outpatient schizophrenia 12-month period . Inclusion criterion . - Ageâ‰¥18 . - Patients enter study must condition appropriate change antipsychotic treatment start new one . Exclusion criterion . - Diagnosis metabolic syndrome . - Diagnosis diabetes mellitus type II . - The patient never expose antipsychotic drug . - One study treatment clearly contraindicate . Recruitment . The study conduct broad array clinical setting order provide generalizable practically relevant study finding . The recruitment period last 12 month participate center . Study design . The GiSAS study multi-centre RCT involve 80 italian psychiatric service recruit 800 patient affected schizophrenia . In non-selected sample schizophrenic patient , hypothesize significant difference overall safety , tolerability acceptability aripiprazole , olanzapine haloperidol consequently effectiveness . It pragmatic trial . Thus , participant select represent broad range `` real-world '' patient , include comorbid condition ( i.e . substance use disorder , medical problem . Patients assess : - baseline ( subject ) ; - monotherapy treatment stop ; - 12 month ( subject ) . Pharmacological treatment . In study , follow drug test : ( ) aripiprazole , ( b ) olanzapine , ( c ) haloperidol . All treatment medication non-blinded . After randomization , assign drug prescribe accord usual care practice . Patients prescribed daily oral dose assign drug , base individual response side-effects . For patient already take antipsychotic medication prior study entry , taper previous medication period four week allow . All drug use arm GiSAS trial currently license market Italy treatment schizophrenia . No antipsychotic medication allow . Concomitant psychotropic medication ( e.g . benzodiazepine , antidepressant ) use non-psychotropic drug allow routinely record . Primary outcome . The measure effectiveness retention patient assign treatment 12 month . The measure tolerability onset metabolic syndrome 12 month ( primary endpoint ) . Switching another antipsychotic , add second antipsychotic stop antipsychotic treatment consider drug discontinuation . Reasons discontinuation register take account create secondary outcome . In order capture whether , participant stop assign treatment add concomitant medication , patient ' ongoing treatment monitor least month . The primary endpoint ( i.e . Metabolic Syndrome ) assess centrally blind independent observer . All statistical analysis blind include randomized subject follow intent-to-treat principle .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Haloperidol</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<mesh_term>Haloperidol decanoate</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<criteria>men woman , 18 year age , meet DSMIV criterion schizophrenia , base upon Mini International Neuropsychiatric Interview ; patient enter study must , accord judgment consultation physician , condition appropriate ( ) start treatment oral antipsychotic medication ( b ) change antipsychotic treatment . diagnosis metabolic syndrome , define fulfil least 3 diagnostic criterion metabolic syndrome derive Adult Treatment Protocol III ( ATP III ) ; diagnosis diabetes mellitus type II ; presence organic condition clearly contraindicate treatment one study drug , e.g. , pregnancy breastfeeding ; one study treatment positively know ineffective tolerable consequently contraindicate ; patient never expose antipsychotic drug ; accord clinician 's opinion , unlikely patient follow whole duration study ( 1 year ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Pragmatic RCT</keyword>
	<keyword>Aripiprazole</keyword>
	<keyword>Olanzapine</keyword>
	<keyword>Haloperidol</keyword>
	<keyword>Metabolic syndrome</keyword>
	<keyword>Drug discontinuation</keyword>
</DOC>